5,800 Shares in Pharvaris (NASDAQ:PHVS) Acquired by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS bought a new stake in shares of Pharvaris (NASDAQ:PHVS) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 5,800 shares of the company’s stock, valued at approximately $111,000.

A number of other hedge funds also recently modified their holdings of PHVS. Public Employees Retirement System of Ohio purchased a new stake in Pharvaris in the 3rd quarter worth about $57,000. Barclays PLC purchased a new stake in shares of Pharvaris during the third quarter worth $106,000. Palumbo Wealth Management LLC acquired a new stake in shares of Pharvaris during the 4th quarter valued at about $196,000. Jane Street Group LLC bought a new stake in shares of Pharvaris in the 3rd quarter valued at approximately $526,000. Finally, Geode Capital Management LLC increased its holdings in Pharvaris by 18.4% in the third quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock worth $685,000 after buying an additional 5,753 shares during the last quarter.

Pharvaris Price Performance

Shares of NASDAQ:PHVS opened at $11.90 on Friday. The stock has a market capitalization of $622.25 million, a P/E ratio of -4.25 and a beta of -2.84. The business has a 50-day moving average of $15.66 and a two-hundred day moving average of $18.41. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $25.50.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Monday, April 7th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.06. As a group, research analysts expect that Pharvaris will post -2.71 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, JMP Securities lifted their target price on shares of Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a research note on Friday, January 31st.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.